Qiming Venture Partners

XSKY Beijing Data Technology Corporation Limited is a China-based technical company focusing on software-defined infrastructure products and services. XSKY builds internet carrier operation experiences, mainstream open-source technology, and enterprise best practices into its products, offering customer future-ready scale-out storage solutions. XSKY is also a major committer to open-source storage system Ceph. It ranks top 3 worldwide and #1 in China for source code contribution in Ceph community. It is the only storage solution partner of Red Hat China. Early adopters for XSKY products are from FSI, transport, telecom, and energy segments. XSKY partners with leading IT companies including Intel, Samsung, Dell, Mellanox et al, focusing on SDS layer, and make win-win with global end user.

Demei Medical specializes in the design and manufacture of sports medicine surgical equipment, intraoperative consumables, and rehabilitation products, with a focus on arthroscopic surgery and sports rehabilitation products.

Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.

Erwan Technology is an online education provider for Chinese middle-class families, focusing on financial investment education. It offers a range of paid educational modules, including live broadcasts, boutique investment courses, and hands-on workshops, to provide users with basic financial skills. Up to now, it has popularized financial education for more than 10 million middle-class students in 34 provincial administrative regions, becoming the largest online investment education platform by users and the top three platforms by revenue. The company was founded in 2016 and is based in Dalian Shi, Liaoning, China.

New Horizon Health is an innovative bio-tech company focusing on early screening and genetic testing services for high-incidence cancer homes. Nuohui Health is committed to reducing the morbidity and mortality of cancer through biotechnological means. It first proposed the slogan of early cancer screening and is committed to promoting early cancer screening into thousands of households so that the public can enjoy convenient and efficient health services .

Mafengwo is a Chinese travel social networking site that allows users to share and explore travel experiences. It features over one million user-generated travel guides and more than five million ratings and reviews, covering a wide range of travel-related information such as hotels, flights, travel routes, visas, and insurance. Since its inception, Mafengwo has served more than 25 million users and emphasizes user experience by continually enhancing its platform for sharing travel insights. Its core product, the Travel Guide, includes information on over 95% of global travel destinations and has achieved over 100 million downloads. In 2012, the platform expanded its offerings by integrating booking services from various providers, thereby enhancing its utility for travelers. The company has also attracted significant investment, raising $15 million in Series B funding to support its growth and development.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Schrödinger develops a computational platform that facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform.

Tuhu is a prominent integrated online and offline platform for automotive services in China, catering to car owners' diverse needs. Operating in over 260 cities, Tuhu offers same-day or next-day delivery and installation services for automobile after-sales products. The company utilizes its website, mobile app, call center, and third-party e-commerce platforms to deliver a digitalized and on-demand service experience. Tuhu's platform addresses a wide range of automotive service demands, including the replacement of tires and chassis parts, as well as auto maintenance, repair, and detailing. By connecting car owners with suppliers and automotive service stores, Tuhu effectively fulfills the requirements of most passenger vehicle models sold in China.

MicroPoint Bioscience, Inc. (微点生物) is a Chinese company dedicated to biochip research and development. The company offers a product series, Lab On a Chip, which is based on micro-electronic mechanical technologies. MicroPoint Biosciences customizes demanded products and services for customers in areas of human health such as medicine, environmental protection, food safety, scientific research, and other application areas. In the area of medicine, MicroPoint Company's bedside immediate diagnosis chip and examination instrument provides low-cost resolutions for early diagnosis and the process monitoring of vascular diseases, tumors, emergency treatments, and operations.

ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China. The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology. The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.

Meituan Bike, previously known as Mobike, is a Chinese bicycle-sharing service that operates a fully station-less model. Founded in January 2015 by Davis Wang Xiao Feng, Hu Wei Wei, and Xia Yi Ping, the company is headquartered in Beijing. Meituan Bike allows users to easily locate and rent bicycles through a mobile application, facilitating convenient transportation for short urban trips. The bicycles are equipped with smart locks and can be reserved via the app, offering a seamless user experience. In April 2018, the company was acquired by Meituan-Dianping for $2.7 billion and was rebranded as Meituan Bike in January 2019 as part of the integration process. The service has grown significantly since its inception, contributing to the development of urban mobility solutions in China.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet medical needs by developing and marketing leading-edge, high quality vaccines for China and other emerging markets at affordable prices.

ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China. The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology. The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005. ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.